PCN2: DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES
نویسندگان
چکیده
منابع مشابه
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
The objectives of this study were to assess the safety and efficacy of darbepoetin alfa (Aranesp) administered every 2 weeks in anemic patients with solid tumors receiving chemotherapy. This was an open-label, randomized, active-controlled, multicenter dose-finding study evaluating a range of every-2-week darbepoetin alfa doses. The active control arm received epoetin alfa (Epogen, Procrit) at ...
متن کاملDarbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-w...
متن کاملEvery-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study d...
متن کاملDose–Conversion Ratio for Epoetin Alfa and Darbepoetin Alfa in Chemotherapy Patients with Anemia and Cancer
INTRODUCTION Anemia is a common complication of myelosuppressive chemotherapies in patients with cancer.1 When untreated, chemotherapy-induced anemia (CIA) may adversely affect the patient’s quality of life and ability to function because of symptoms such as fatigue, weakness, shortness of breath, and impaired mental function.2-4 Red blood cell (RBC) transfusions can be used to correct anemia, ...
متن کاملEffects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
PURPOSE/OBJECTIVES To review the effects on hemoglobin and quality of life of an every-two-week (Q2W) regimen of the erythropoietic agent darbepoetin alfa for treating patients with chemotherapy-induced anemia. DATA SOURCES Published articles and abstracts. DATA SYNTHESIS Darbepoetin alfa Q2W increases hemoglobin in patients with chemotherapy-associated anemia and is well tolerated. Increas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2003
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63922-8